[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461906":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":39,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Bioaraba Health Research Institute","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Corticosteroids","ACTIVE_COMPARATOR","Corticosteroids following Standard Clinical Practice",[13],"Drug: N-acetylcysteine",{"label":15,"type":16,"description":17,"interventionNames":18},"Corticosteroids + N-acetylcysteine","EXPERIMENTAL","Corticosteroids following Standard Clinical Practice plus N-acetylcisteine",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","N-acetylcysteine","Day 1: 150 mg\u002Fkg in 250ml 5% glucose over 30min + 50mgr\u002Fkg in 500ml glucose over 4h + 100mgr\u002Fkg in 1000ml glucose over 16h intravenously.\n\nDay 2-14: 100mgr\u002Fkg in 1000 ml glucose\u002F24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h.",[9,15],null,[27],{"name":28,"affiliation":29,"role":30},"Ana Belén Fernández, Clinic","HUA","PRINCIPAL_INVESTIGATOR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":25,"email":35},"CONTACT","945007000","anabelen.fernandezlaso@osakidetza.eus",{"name":37,"role":33,"phone":34,"phoneExt":25,"email":38},"Inés Pérez, Coordinator","ines.perezfrancisco@osakidetza.eus",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Ana Belén Fernández Laso","RECRUITING","Vitoria-Gasteiz","Álava","01009","Spain","ES",{"type":49,"coordinates":50},"Point",[51,52],-2.67268,42.84998,{"lat":52,"lon":51},[55],{"name":28,"role":33,"phone":34,"phoneExt":25,"email":35},{"type":30,"investigatorFullName":41,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Principal Investigator","100461906","utility-of-the-use-of-n-acetylcysteine-associated-with-conventional-treatment-in-patients-with-severe-acute-alcoholic-hepatitis-maddrey-32-100461906",false,"NCT05294744","Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)","Inclusion Criteria:\n\n* Men and women.\n* Age from 18 to 75 years.\n* Patients with acute alcoholic hepatitis according to AASLD criteria or compatible liver histology.\n* Maddrey score\\> = 32.\n* Acceptance of participation through written informed consent.\n\nExclusion Criteria:\n\n* Any cause of jaundice: acute hepatitis, positive HIV serology, biliary-pancreatic pathology, hemolytic anemia.\n* Allergy or intolerance to N-acetylcysteine and \u002F or corticosteroids.\n* Hepatocarcinoma.\n* Portal cavernomatosis.\n* Portal cavernomatosis.\n* Any disease whose life expectancy is less than 12 months.\n* Patients with nitroglycerin and \u002F or carbamazepine-based treatments.\n* Patients with uncontrolled active infection.\n* Acute kidney disease with creatinine\\> 2.5 mg \u002F dL.\n* Uncontrolled upper gastrointestinal bleeding.\n* Concomitant uncontrolled diseases (HBV, HCV, HIV, TB, DILI, HCC or acute pancreatitis).\n* Multiple organ failure or shock.","ALL","18 Years","75 Years",{"count":68,"type":69},390,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive corticosteroids.",[75],"Alcoholic Hepatitis","2026-01-08",{"date":78,"type":79},"2026-01-12","ACTUAL",{"date":81,"type":79},"2022-10-07",{"date":83,"type":69},"2026-12",{"name":5,"class":6},1]